Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

University Of Maryland, Baltimore

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1807-01-01

Employees: 7.3K

Market Cap: -

Website: http://www.umaryland.edu

Clinical Trials

Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia

Not Applicable

Completed

Conditions: Schizophrenia
Schizoaffective Disorder

Interventions: Behavioral: Cognitive remediation training
Drug: Nicotine polacrilex lozenge

First Posted Date: 2014-02-24

Last Posted Date: 2019-09-12

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 31

Registration Number: NCT02069392

Locations: 🇺🇸
Maryland Psychiatric Research Center, Baltimore, Maryland, United States

Tryptophan MRI in People With Schizophrenia and Healthy Controls

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Tryptophan
Drug: Placebo

First Posted Date: 2014-02-20

Last Posted Date: 2024-07-30

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 93

Registration Number: NCT02067975

Locations: 🇺🇸
Maryland Psychiatric Research Center, Catonsville, Maryland, United States

Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention

Not Applicable

Completed

Conditions: HIV

Interventions: Behavioral: Personal Approaches to Treatment Choices for HIV
Behavioral: Stress Reduction Skills Program

First Posted Date: 2014-02-05

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 50

Registration Number: NCT02055417

Locations: 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System

Not Applicable

Active, not recruiting

Conditions: Unresectable Pancreatic Cancer

Interventions: Device: NanoKnife IRE System

First Posted Date: 2014-01-22

Last Posted Date: 2024-02-16

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 4

Registration Number: NCT02041936

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

Telehome Monitoring for Chronic Disease Management

Not Applicable

Completed

Conditions: Diabetes Mellitus
Heart Failure
Hypertension
Pulmonary Disease, Chronic Obstructive

Interventions: Other: Telehome Care Monitoring

First Posted Date: 2014-01-14

Last Posted Date: 2022-01-27

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 23

Registration Number: NCT02035566

Locations: 🇺🇸
Chesapeake-Potomac Home Health Agency, Hughesville, Maryland, United States
🇺🇸
Garrett County Health Department Home Health Agency, Oakland, Maryland, United States

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

Phase 1

Withdrawn

Conditions: Large Cell Neuroendocrine (NE) Tumors
Small Cell Lung Cancer (SCLC)
Neuroendocrine (NE) Tumors

Interventions: Drug: Rhenium Re 188-P2045

First Posted Date: 2014-01-08

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT02030184

Locations: 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States

Incisional Negative Pressure Dressing on Clean Closed Groin Incisions

Not Applicable

Withdrawn

Conditions: Complication of Surgical Procedure

Interventions: Other: Standard of Care wound therapy
Device: Incisional Neg Pressure Wound Therapy (Prevena™)

First Posted Date: 2013-12-10

Last Posted Date: 2023-05-06

Lead Sponsor: University of Maryland, Baltimore

Registration Number: NCT02006511

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab plus Pertuzumab
Drug: Hormonal Therapy with Anastrozole and Fulvestrant
Drug: Chemotherapy with Eribulin

First Posted Date: 2013-12-04

Last Posted Date: 2022-05-27

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 2

Registration Number: NCT02000596

Locations: 🇺🇸
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States

Lamotrigine Bioequivalence

Phase 4

Completed

Conditions: Epilepsy

Interventions: Drug: Brand lamotrigine
Drug: Generic lamotrigine

First Posted Date: 2013-11-27

Last Posted Date: 2020-12-01

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 35

Registration Number: NCT01995825

Locations: 🇺🇸
University of Maryland, Baltimore, Maryland, United States

Borderline Pancreas Study: FOLFIRINOX +SBRT

Early Phase 1

Completed

Conditions: Resectable Pancreatic Cancer

Interventions: Other: Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable
Drug: -Oxaliplatin 85 mg/m2 IV on Day 1
Drug: -Irinotecan 180 mg/m2 IV on Day 1
Drug: -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours

First Posted Date: 2013-11-25

Last Posted Date: 2019-08-19

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 8

Registration Number: NCT01992705

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy